Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.84 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.84 |
| ▸ | CHKA | P35790 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24023622 | 1.00 | CYP2D6 (0.89) | CYP2D6CYP2C19HRH3HRH4CHKA | |
| SCHEMBL24023625 | 1.00 | CYP2D6 (0.89) | CYP2D6CYP2C19HRH3HRH4CHKA | |
| SCHEMBL1690956 | 0.98 | CYP2D6 (0.85) | CYP2D6CYP2C19HRH3HRH4CHKA | |
| SCHEMBL16226080 | 0.88 | SIGMAR1 (0.78) | CYP2D6CYP2C19HRH3HRH4CHKA | |
| SCHEMBL8327 | 0.87 | SIGMAR1 (0.77) | CYP2D6CYP2C19HRH3HRH4ALDH1A1 | |
| SCHEMBL11585348 | 0.87 | SIGMAR1 (0.77) | CYP2D6CYP2C19HRH3HRH4ALDH1A1 | |
| SCHEMBL26532 | 0.87 | SIGMAR1 (0.77) | CYP2D6CYP2C19HRH3HRH4ALDH1A1 | |
| SCHEMBL11141692 | 0.87 | SIGMAR1 (0.77) | CYP2D6CYP2C19HRH3HRH4ALDH1A1 | |
| SCHEMBL688047 | 0.87 | SIGMAR1 (0.77) | CYP2D6CYP2C19HRH3HRH4ALDH1A1 | |
| Bromide SCHEMBL10730905 | 0.85 | SIGMAR1 (0.74) | CYP2D6CYP2C19HRH3HRH4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| EP-2373627-A1 | 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | N.V. Organon (NL) | 2011-10-12 | — | — | EP | disclosed |
| US-7960560-B2 | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | N. V. ORGANON | 2010-06-10 | — | — | US | disclosed |
| WO-2010063721-A1 | 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | N.V. ORGANON (NL) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | OPRM1, OR10J3, OPRD1 | CYP2D6 452/4885CYP2C19 1442/4885HRH3 32/4885 |
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | CYP2D6 1576/4885CYP2C19 4015/4885HRH3 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.